Matches 1 - 50 out of 341 1 2 3 4 5 6 7 >


Match Document Document Title
9012494 Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors  
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2;L represents a C1-3alkyl linker optionally substituted with...
8992989 Sustained-release formulations of topiramate  
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the...
8980942 Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same  
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the...
8980941 Controlled Cannabis decarboxylation  
The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (Δ9-THC) and other cannabinoid medicinal substances are decarboxylated...
8980940 Stable cannabinoid compositions and methods for making and storing them  
A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of...
8974363 Topical medicaments and methods for photodynamic treatment of disease  
New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active...
8969406 Use of compound for inhibiting glutathione s-transferase omega 1 activity and method for synthesizing the same  
A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group...
8937097 Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol  
Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by...
8933116 Gamma secretase inhibitors  
Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims....
8927594 Compounds from soft coral, method of preparation and pharmaceutical uses thereof  
The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide...
8906416 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders  
The invention relates to compound of generic formula (I) in which: R1 and R2 represent: OH, a hydrogen atom, a C1-C6 alkyl radical a C1-C6 alkoxy radical, a halogen, or OCOR3; R3 represents: a...
8906956 Composition comprising (−)-Δ9-trans-tetrahydrocannabinol  
A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ8 tetrahydrocannabinol, (−)-Δ9-trans-tetrahydrocannabinol or a...
8883847 Compositions and methods of treatment using modulators of motoneuron diseases  
The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); a method for measuring the state of activity of this...
8853263 Co-therapy for the treatment of epilepsy and related disorders  
The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically...
8829043 Oligome-cannabinoid conjugates  
The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes,...
8808734 Cannabinoid formulations  
The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.
8771760 Method for the treatment of constipation  
The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and...
8758826 Cannabinoid receptor binding agents, compositions, and methods  
A composition comprising a cannabinoid receptor binding agent attached to a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose....
8748480 Methods for treating opioid tolerance  
The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in...
8735444 Fluorinated rhodamines as photostable fluorescent dyes for labelling and imaging techniques  
The present invention relates to novel fluorinated 3,6-diaminoxanthene compounds derived from the basic structural formula (I) and to their uses as photostable fluorescent dyes, e.g. for...
8710070 Opioid-ketamine and norketamine codrug combinations for pain management  
The present invention relates to the field of pain management, and more particularly to synergistic codrugs comprising an opioid and ketamine or norketamine which have been combined to form a...
8710069 Opioid-nornicotine codrugs combinations for pain management  
The present invention relates to the field of pain management, and more particularly to synergistic codrugs comprising an opioid and nornicotine which have been combined to form a single chemical...
8680140 Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms  
Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described...
8663683 Sustained-release formulations of topiramate  
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the...
8647830 Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease  
The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a...
8642080 Drug delivery system comprising polyoxazoline and a bioactive agent  
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of...
8642645 Pharmaceutical composition comprising Cannabinoids  
The present invention relates to a pharmaceutical composition comprising Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid,...
8637087 Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids  
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses...
8628796 Room-temperature stable dronabinol formulations  
A room temperature stable cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation is dronabinol in an oil-based carrier contained within a hard gelatin capsule.
8629177 Nanoencapsulated delta-9-tetrahydrocannabinol  
Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids as a therapeutic. One embodiment of...
8569360 Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling  
Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met obtained by virtual screening, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are...
8552057 Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases  
Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological heath and prevention of age-related neurodegeneration, such as AD, have been developed. These select...
8546342 Composition for treating mental health disorders  
A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds...
8497299 Compositions including quinonoid derivatives of cannabinoids for therapeutic use  
The present invention relates to cannabinoic quinone compounds, and especially to their medical use. In particular five cannabinoic quinones, designated HU-331, HU-336, HU-345, HU-395 and HU-396,...
8476312 Composition comprising (−)-Δ9-trans-tetrahydrocannabinol  
A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ8 tetrahydrocannabinol, (−)-Δ9-trans-tetrahydrocannabinol or a...
8476307 Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof  
A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.
8475776 Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis  
Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.
8455252 Materials and methods for sensitizing multidrug resistant cells  
Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that...
8410164 Reagent for measurement of active oxygen  
A compound represented by the formula (I) (R1 represents an aryl group such as hydroxyphenyl group, R2 represents 2-carboxyphenyl group etc., and R3 and R4 represent —(CH2)p—N(R5)(R6) (R5 and R6...
8399510 Method of activating NK cells  
The present invention provides a method of mediating hypo-activation of NK cells. Methods of the present invention comprise administering to a subject an effective amount of broad acting...
8394850 Fluorescent probe specific to hydrogen peroxide  
A compound represented by the following general formula (IA) or (IB) (R1 represents an electron withdrawing substituent, R2 and R3 represent a hydrogen atom or a halogen atom; R4 and R3 represent...
8389566 Prostaglandins and analogues as agents for lowering intraocular pressure  
The present invention relates to cyclopentane heptenoic acid-5-cis-2-(3α-hydroxy or lower alkyloxy-5-thienylpentyl)-3, 5-dihydroxy, [1α, 2β, 3α, 5α] compounds, lower alkyl, hydroxyl lower alkyl...
8389568 IDO inhibitors and methods of use thereof  
Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.
8361734 Xanthurenic acid derivative pharmaceutical compositions and methods related thereto  
The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: or a prodrug or pharmaceutically acceptable salt...
8357701 Galactokinase inhibitors  
Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase...
8354447 mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression  
Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGluRs belonging to at least two different groups. In one embodiment, there are...
8318699 Tumor necrosis factor inhibitors  
The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and...
8298580 Sustained-release formulations of topiramate  
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the...
8299116 CCI-779 concentrate formulations  
This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid...
8263644 Cytotoxic xanthone compounds  
The present invention relates to xanthone compounds isolated from the plant Psorospermum molluscum Hochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.

Matches 1 - 50 out of 341 1 2 3 4 5 6 7 >